In diet-induced obese C57BL/6J mice treated with liraglutide for 14 days, 16S rRNA sequencing of 7.1 million sequences identified 21 amplicon sequence variants as primary drivers of microbiome restructuring. Nine ASVs linked to Lactobacillus gasseri, L. paragasseri, L. johnsonii, and Leptogranulimonas caecicola surged during treatment, while 12 ASVs representing fermentative genera — Romboutsia, Faecalicatena, and Oscillibacter — were suppressed. Weight loss emerged by Day 4, and microbial shifts largely reversed within 7 days of washout.
The finding that liraglutide enriches bile acid- and mucin-associated taxa while suppressing carbohydrate fermenters is mechanistically coherent: GLP-1 signaling slows gastric emptying, altering luminal substrate availability and potentially favoring organisms adapted to bile-rich, mucus-proximal niches like Lactobacillus species. This microbiome signature partially mirrors patterns seen with caloric restriction, raising the question of how much of liraglutide's metabolic benefit is microbiome-mediated versus direct receptor signaling — a distinction this study cannot resolve.
Critical limitations deserve weight: this is an all-male mouse model, and human gut microbiome responses to GLP-1 agonists like semaglutide show considerably more interindividual variation. The 7-day washout window is short, leaving longer-term reversibility uncharacterized. Nevertheless, the inclusion of baseline lean-phase samples — allowing drug effects to be disentangled from obesity-driven dysbiosis — is a meaningful methodological strength. Overall, this is solid confirmatory mechanistic groundwork, incrementally advancing the case that GLP-1 therapies act partly through host-microbiome crosstalk.